Guidelines from the American Association for the Study of Liver Disease (AASLD) recommend HCC surveillance with abdominal ultrasound every 6 months with or without alpha fetoprotein (AFP) in patients with cirrhosis7. The gene discussed is AFP; the disease is hepatocellular carcinoma.